Description

Tirzepatide is a dual receptor agonist that targets both GLP-1 and GIP pathways, making it an important compound in contemporary metabolic research. Studies investigate how simultaneous activation of these incretin-related receptors influences glucose homeostasis, appetite signalling, energy balance and broader metabolic processes. Its dual-pathway mechanism has generated significant research interest compared with compounds that interact with a single receptor pathway. Tirzepatide continues to be evaluated across laboratory and clinical research environments investigating incretin biology and metabolic regulation. This 10mg × 10 vial presentation is intended to support controlled research into GLP-1 and GIP receptor activity and related metabolic signalling pathways.